RenovoRx, Inc.
NASDAQ: RNXT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Shaun R. Bagai
- Employees
- 10
- Headquarters
- Mountain View, United States
- IPO year
- 2021
- Market cap
- $35.5M
- Website
- https://renovorx.com
Loading RNXT…
Loading profile data…Frequently asked questions about RNXT
What does RenovoRx, Inc. (RNXT) do?
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clin...
Where does RNXT trade?
RenovoRx, Inc. (RNXT) trades on the NASDAQ Capital Market.
What sector is RNXT in?
RenovoRx, Inc. (RNXT) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of RenovoRx, Inc.?
Shaun R. Bagai is the chief executive officer of RenovoRx, Inc. (RNXT).
Where is RenovoRx, Inc. headquartered?
RenovoRx, Inc. is headquartered in United States.
Does RNXT pay a dividend?
RenovoRx, Inc. (RNXT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did RNXT go public?
RenovoRx, Inc. (RNXT) completed its initial public offering in 2021.